The V-set and Immunoglobulin Domain Containing (VSIG) family is a group of proteins characterized by the presence of V-set and immunoglobulin (Ig) domains. These domains are typically found in molecules involved in immune system functioning and cell adhesion. This family is currently comprised of eight members, including VSIG1, VSIG2, VSIG3, VSIG4, VSIG8, VSIG9, VSIG10, and VSIG10 L, which are all type I transmembrane proteins. Members of the VSIG family are predominantly expressed in the immune system and various epithelial tissues, suggesting a role in immune responses and epithelial cell interactions. The function of VSIG proteins often involves cell-cell adhesion, signaling, and modulation of immune responses, although the specific roles can vary among different family members. In terms of signaling, VSIG proteins are known to participate in a variety of pathways, including those that regulate cell proliferation, differentiation, and apoptosis, particularly in the context of immune and epithelial cells. Furthermore, some VSIG family members have been implicated in the development and progression of certain cancers, indicating their potential as targets or biomarkers in oncology.
Targeting V-set and Immunoglobulin Domain Containing (VSIG) proteins using small molecules can provide valuable insights into the mechanistic aspects of T-cell responses and immune suppressive microenvironments. VSIG proteins are implicated in immune cell interactions and signaling pathways that are crucial for the regulation of T-cell activity and immune tolerance. By disrupting or inhibiting VSIG proteins, researchers can observe changes in T-cell behavior, helping to elucidate their role in immune activation and suppression.
関連項目
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | ¥1207.00 | ||
一种强效的 CHK1 和 CHK2 抑制剂,用于癌症的临床前研究。 检查点激酶(CHK)抑制剂 可能影响细胞周期控制机制,其中 VSIG 蛋白可能起作用。 | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | ¥711.00 ¥2719.00 | 136 | |
MEK 抑制剂可能会干扰与 VSIG 相关的 MAPK/ERK 信号通路。 | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | ¥733.00 ¥3012.00 | 257 | |
JNK 抑制剂,可能会影响与 VSIG 相关的应激反应途径。 | ||||||
LY2606368 | 1234015-52-1 | sc-507521 sc-507521A sc-507521B sc-507521C sc-507521D sc-507521E | 5 mg 10 mg 25 mg 100 mg 1 g 10 g | ¥1986.00 ¥3384.00 ¥5642.00 ¥21435.00 ¥90252.00 ¥423075.00 | ||
一种选择性CHK1抑制剂,正在接受各种类型的临床试验研究。检查点激酶(CHK)抑制剂可能影响VSIG蛋白可能发挥作用的细胞周期控制机制。 | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | ¥993.00 ¥3858.00 | 284 | |
p38 MAPK 抑制剂可以改变与 VSIG 相关的炎症反应途径。 | ||||||
PF 477736 | 952021-60-2 | sc-362781 sc-362781A | 5 mg 25 mg | ¥1275.00 ¥4772.00 | ||
一种强效选择性 CHK1 抑制剂 检查点激酶(CHK)抑制剂可能会影响细胞周期控制机制,而 VSIG 蛋白可能在其中发挥作用。 | ||||||
SCH 900776 | 891494-63-6 | sc-364611 sc-364611A | 5 mg 10 mg | ¥2877.00 ¥3813.00 | ||
一种选择性 CHK1 抑制剂已在临床试验中进行研究 检查点激酶(CHK)抑制剂可能会影响细胞周期控制机制,而 VSIG 蛋白可能在其中发挥作用。 |